相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance
Katherine E. Fleming-Dutra et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Effectiveness of BNT162b2 against COVID-19 in adolescents
Annabel A. Powell et al.
LANCET INFECTIOUS DISEASES (2022)
BNT162b2 Protection against the Omicron Variant in Children and Adolescents
A. M. Price et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022
Ashley L. Fowlkes et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022
Nicola P. Klein et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022
Chiara Sacco et al.
LANCET (2022)
Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years
Sara Y. Tartof et al.
JAMA NETWORK OPEN (2022)